Werewolf Therapeutics Reports Promising Phase 1 Data for WTX-124 and WTX-330 in Advanced Cancer Trials
I'm PortAI, I can summarize articles.
Werewolf Therapeutics Inc. reported promising Phase 1 data for its INDUKINE™ programs, WTX-124 and WTX-330, in advanced cancer trials. WTX-124 showed a 30% response rate in melanoma patients, while WTX-330 demonstrated antitumor activity. The company plans further updates in 2026 and aims for IND filings for WTX-1011 and WTX-2022 by mid-2027. This information was originally published by Werewolf Therapeutics via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments